Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Maria D. Panno"'
Autor:
Bram F. Coolen, Wouter H. Nijhof, Joanne Verheij, Loek P. Smits, Jaap Stoker, Jurgen H. Runge, Aart J. Nederveen, Ulrich Beuers, Maria D. Panno, Erik S.G. Stroes, Max Nieuwdorp
Publikováno v:
Radiology, 278(3), 782-791. Radiological Society of North America Inc.
Radiology, 278(3), 782-91. Radiological Society of North America Inc.
Smits, L P, Coolen, B F, Panno, M D, Runge, J H, Nijhof, W H, Verheij, J, Nieuwdorp, M, Stoker, J, Beuers, U H, Nederveen, A J & Stroes, E S 2016, ' Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease : A Proof-of-Concept Study ', Radiology, vol. 278, no. 3, pp. 782-91 . https://doi.org/10.1148/radiol.2015150952
Radiology, 278(3), 782-91. Radiological Society of North America Inc.
Smits, L P, Coolen, B F, Panno, M D, Runge, J H, Nijhof, W H, Verheij, J, Nieuwdorp, M, Stoker, J, Beuers, U H, Nederveen, A J & Stroes, E S 2016, ' Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease : A Proof-of-Concept Study ', Radiology, vol. 278, no. 3, pp. 782-91 . https://doi.org/10.1148/radiol.2015150952
Purpose: To (a) study the optimal timing and dosing for ultrasmall superparamagnetic iron oxide particle (USPIO)-enhanced magnetic resonance (MR) imaging of the liver in nonalcoholic fatty liver disease, (b) evaluate whether hepatic USPIO uptake is d
Publikováno v:
Clinical Lipidology. 9:19-32
Lomitapide (Juxtapid® and Lojuxta®; Aegerion Pharmaceuticals, Inc., MA, USA), an orally administered inhibitor of the microsomal triglyceride transfer protein, inhibits the synthesis and secretion of ApoB-containing lipoproteins and, thus, reduces
Autor:
Vincenza Valenti, Antonina Giammanco, V. Ingrassia, Carlo M. Barbagallo, Maria D. Panno, Angelo B. Cefalù, A. Ganci, Rossella Spina, Maurizio Averna, Davide Noto
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 35(12)
Objective— Cyclic AMP responsive element–binding protein 3–like 3 ( CREB3L3 ) is a novel candidate gene for dominant hypertriglyceridemia. To date, only 4 kindred with dominant hypertriglyceridemia have been found to be carriers of 2 nonsense m